Bit Capital Gmb H Arvinas, Inc. Transaction History

Bit Capital Gmb H

$1.26 Trillion
Q4 2024

A detailed history of Bit Capital Gmb H transactions in Arvinas, Inc. stock. As of the latest transaction made, Bit Capital Gmb H holds 263,527 shares of ARVN stock, worth $4.66 Million. This represents 0.4% of its overall portfolio holdings.

Number of Shares

263,527

Previous 67,281 291.68%

Holding current value

$4.66 Million

Previous $1.66 Billion 204.85%

% of portfolio

0.4%

Previous 0.15%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 12, 2025	BUY	$17.83 - $28.04 $3.5 Million - $5.5 Million	196,246 Added 291.68%	263,527 $5.05 Billion
Q3 2024 Feb 12, 2025	SELL	$23.66 - $32.73 $323,929 - $448,106	-13,691 Reduced 16.91%	67,281 $1.66 Billion
Q2 2024 Feb 12, 2025	SELL	$24.46 - $40.4 $1.51 Million - $2.49 Million	-61,734 Reduced 43.26%	80,972 $2.16 Billion
Q1 2024 Feb 12, 2025	BUY	$36.38 - $52.31 $254,077 - $365,333	6,984 Added 5.15%	142,706 $5.89 Billion
Q4 2023 Feb 12, 2025	BUY	$14.19 - $42.33 $1.53 Million - $4.57 Million	107,918 Added 388.14%	135,722 $5.59 Billion
Q3 2023 Feb 12, 2025	BUY	$19.64 - $28.21 $29,460 - $42,315	1,500 Added 5.7%	27,804 $546 Million
Q2 2023 Feb 12, 2025	BUY	$21.73 - $31.43 $50,326 - $72,791	2,316 Added 9.65%	26,304 $653 Million
Q1 2023 Feb 12, 2025	BUY	$26.15 - $37.26 $359,039 - $511,579	13,730 Added 133.85%	23,988 $655 Million
Q4 2022 Feb 12, 2025	BUY	$32.47 - $57.24 $92,019 - $162,218	2,834 Added 38.17%	10,258 $351 Million
Q3 2022 Feb 12, 2025	BUY	$41.87 - $57.99 $120,334 - $166,663	2,874 Added 63.16%	7,424 $330 Million
Q1 2022 Feb 12, 2025	BUY	$60.27 - $81.57 $274,228 - $371,143	4,550 New	4,550 $306 Million

Others Institutions Holding ARVN

# of Institutions

227

Shares Held

68.2M

Call Options Held

226K

Put Options Held

285K

View Full List

About ARVINAS, INC.

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $941M
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

More about ARVN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bit Capital Gmb H, based on Form 13F filings with the SEC.

News

Stay updated on Bit Capital Gmb H with notifications on news.

Account